Key clinical point: There are very limited data from phase 3 trials to judge racial differences in response to therapies for psoriasis.
Major finding: Of psoriasis trials with ethnoracial data, 85.8% of participants were White, 19.5% were Hispanic, 9.2% were Asian, and 3.1% were black.
Data source: A cross-sectional analysis of the clinicaltrials.gov database.
Disclosures: The research had no funding source. Three of the nine authors reported financial relationships with pharmaceutical companies.
Reddy VD et al. Br J Dermatol. 2020 Sep 17. doi: 10.1111/bjd.19468.